Overview
Legality, special rules, and flavor text
Rules
The first nonlegendary artifact spell you cast each turn has casualty 2. (As you cast it, you may sacrifice a creature with power 2 or greater. When you do, copy it. A copy of an artifact spell becomes a token.) Whenever you sacrifice another creature, put a +1/+1 counter on Ashad.
Rulings
Casualty 2 means "As an additional cost to cast this spell, you may sacrifice a creature with power 2 or greater." and "When you cast this spell, if a casualty cost was paid for it, copy it. If the spell has any targets, you may choose new targets for the copy." — If you pay the casualty cost of a spell, the copy will resolve before the original spell. — The copy of the spell is created on the stack, so it's not "cast." Abilities that trigger when a player casts a spell won't trigger. — You may sacrifice only one creature to pay a spell's casualty cost, and you copy the spell only once.
Card details
Printing, type line, and catalog data
Identity & printing
- Card ID
- WHO-993--foil
- Name
- Ashad, the Lone Cyberman (Foil)
- Number
- 993
- Rarity
- Rare
- Variant
- Foil
Set, artist & references
- Artist
- Eric Wilkerson
- Language
- English
- Set name
- Doctor Who
- Game name
- Magic: The Gathering
Battle
Abilities, attacks, weakness & resistance
Extended catalog fields
Extra Scrydex fields not shown in card details above
Raw payload (remaining)
Other game-specific keys from the API
- Supertypes
- Legendary
eBay market prices
Sold and listed medians — tap a grade for comps
More conditions (eBay)
Add LP / MP / HP / DMG or a slab grade (PSA 8, ACE 9, BGS 9.5, …). Everyone sees the same prices; scheduled refreshes include these variants.
Listed on marketplace
Vendors currently listing this card/product on our marketplace. Click through to view or purchase (purchase flow coming soon).
No marketplace listings for this card right now.
More in this set
Other cards from Doctor Who
Comments
Share your thoughts on this card — condition, value, pull rates, etc.
to comment.
No comments yet. Be the first to share your thoughts.












